EC Number   |
|---|
    1.14.14.19 | isoform P450 17A1 in complex with either abiraterone or progesterone, sitting drop vapor diffusion method, using 100 mM sodium HEPES buffer (pH 7.5), 50 mM MgCl2, and 20-30% (w/v) polyethylene glycol monomethyl ether 3550 |
| 1.14.14.19 | isoform P450 17A2 in complex with either abiraterone or progesterone, sitting drop vapor diffusion method, using 100 mM sodium HEPES buffer (pH 7.5), 50 mM MgCl2, and 20-30% (w/v) polyethylene glycol monomethyl ether 3550 |
| 1.14.14.19 | molecular docking of inhibitors to the active site |
| 1.14.14.19 | mutant enzyme A105L in complex with progesterone, pregnenolone, 17alpha-hydroxypregnenolone, or abiraterone is crystallized by the hanging drop vapor diffusion method using 100 mM Tris-HCl, pH 8.5, 25% (w/v) PEG 4000, 150 mM magnesium chloride hexahydrate, and 4-6% (v/v) glycerol. Mutant enzyme A105L in complex with 17alpha-hydroxyprogesterone is crystallized by the hanging drop vapor diffusion method using 175 mM Tris-HCl, pH 8.5, 30% (w/v) PEG 3350, 250 mM lithium sulfate, and 3% (v/v) glycerol |
